Wall Street analyst calls on November 19, 2026: Nvidia, Apple, Box and Strategy

In a November 19, 2026 roundup of Wall Street analyst calls, firms highlighted AI-related businesses, insurers and several companies receiving new coverage. The ratings and price targets below are the firms’ views, not forecasts of actual returns.

Technology and AI

  • Wolfe initiated coverage of Anthropic with an outperform rating, calling it “best-in-class” and pointing to its growth prospects.
  • JPMorgan reiterated an overweight rating on Apple. It said its survey found iPhone purchase intent at a five-year high, led by existing users looking to upgrade, while interest from people switching brands had moderated for a second consecutive year.
  • UBS upgraded Box to buy from neutral, citing what it described as accelerating AI-driven growth. It also upgraded MongoDB to buy from neutral, citing durable growth.
  • Barclays initiated Synopsys at overweight, pointing to demand for chip-design software and AI tools. StoneX initiated NXP Semiconductors at buy.
  • Daiwa reiterated an outperform rating on Nvidia but cut its price target to $185 from $245. It said the company’s results were strong while raising questions about the durability of AI investment and eventual CEO succession.
  • Morgan Stanley reiterated an overweight rating on SpaceX in the roundup, describing it as a potential pick for what the firm called an “off-the-grid” portfolio.

Insurance, health care and other businesses

Wells Fargo upgraded insurance brokers Brown & Brown and Marsh & McLennan to overweight from equal weight. UBS upgraded Unum Group to buy from neutral, saying the market underappreciated potential earnings benefits from improving mortality. UBS also upgraded Reinsurance Group of America to buy from neutral and raised its price target to $325 from $236.

In health care, Leerink upgraded Abbott Laboratories to outperform from market perform. Bank of America initiated Viridian Therapeutics at buy with a $47 price objective, while Piper Sandler initiated Outlook Therapeutics at overweight with a $4 price target.

Other new buy or overweight calls included StoneX on Harley-Davidson, Barclays on Vylor and BBB Foods, Rothschild & Co Redburn on Super Group, and Piper Sandler on Kingstone Companies. Oppenheimer initiated Unusual Machines, HawkEye 360 and Swarmer at outperform.

Upgrades and a downgrade

Citizens upgraded Expeditors International to market outperform from market perform, with a $240 price target. BMO upgraded Bloom Energy to outperform from market perform while lowering its target to $230 from $260. B. Riley upgraded AST SpaceMobile to buy from hold, saying its assessment of the shares’ risk and potential reward had improved.

Monness Crespi Hardt downgraded Strategy to sell from neutral. The firm cited concerns about bitcoin, the company’s leverage and the premium it said the shares carried over the value of its bitcoin holdings.

Further reading